Federico Cappuzzo

48.3k total citations · 14 hit papers
360 papers, 24.6k citations indexed

About

Federico Cappuzzo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Federico Cappuzzo has authored 360 papers receiving a total of 24.6k indexed citations (citations by other indexed papers that have themselves been cited), including 288 papers in Pulmonary and Respiratory Medicine, 268 papers in Oncology and 66 papers in Molecular Biology. Recurrent topics in Federico Cappuzzo's work include Lung Cancer Treatments and Mutations (255 papers), Lung Cancer Research Studies (102 papers) and Colorectal Cancer Treatments and Studies (91 papers). Federico Cappuzzo is often cited by papers focused on Lung Cancer Treatments and Mutations (255 papers), Lung Cancer Research Studies (102 papers) and Colorectal Cancer Treatments and Studies (91 papers). Federico Cappuzzo collaborates with scholars based in Italy, United States and Germany. Federico Cappuzzo's co-authors include Tony Mok, Pasi A. Jänne, Lucio Crinò, Marileila Varella‐Garcia, Tarek Mekhail, Robert M. Jotte, Marcin Kowanetz, Luca Toschi, Stefania Bartolini and Delvys Rodríguez‐Abreu and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Federico Cappuzzo

343 papers receiving 24.1k citations

Hit Papers

MET Amplification Leads t... 2007 2026 2013 2019 2007 2018 2014 2019 2010 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
    2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
  2. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
    2018 2.6k citations Mark A. Socinski, Federico Cappuzzo et al. profile →
  3. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
    2014 2.3k citations Benjamin Solomon, Tony Mok et al. profile →
  4. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
    2019 1.1k citations Tarek Mekhail, Federico Cappuzzo et al. profile →
  5. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
    2010 917 citations Federico Cappuzzo et al. profile →
  6. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
    2019 688 citations Tony Mok, Federico Cappuzzo et al. profile →
  7. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    2014 492 citations Armida D’Incecco, Elisa Rossi et al. profile →
  8. Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients
    2009 455 citations Federico Cappuzzo, Antonio Marchetti et al. Journal of Clinical Oncology profile →
  9. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
    2020 405 citations Federico Cappuzzo, Mark A. Socinski et al. Journal of Thoracic Oncology profile →
  10. IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
    2021 316 citations Mark A. Socinski, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →
  11. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
    2018 285 citations Benjamin Solomon, Yi‐Long Wu et al. Journal of Clinical Oncology profile →
  12. Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
    2016 268 citations Federico Cappuzzo, D. Ross Camidge et al. Journal of Thoracic Oncology profile →
  13. New promises and challenges in the treatment of advanced non-small-cell lung cancer
    2024 116 citations Luis Paz‐Ares, Federico Cappuzzo et al. profile →
  14. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
    2023 102 citations Mark A. Socinski, Federico Cappuzzo et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Federico Cappuzzo 16.9k 16.9k 7.0k 4.3k 1.8k 360 24.6k
D. Ross Camidge 15.0k 0.9× 16.9k 1.0× 8.6k 1.2× 4.6k 1.1× 1.9k 1.1× 539 24.2k
Giorgio V. Scagliotti 17.1k 1.0× 19.6k 1.2× 8.4k 1.2× 5.3k 1.2× 1.5k 0.8× 480 29.7k
Lesley Seymour 13.8k 0.8× 13.6k 0.8× 5.3k 0.8× 3.8k 0.9× 1.2k 0.6× 258 22.2k
Alan Sandler 17.9k 1.1× 15.6k 0.9× 5.9k 0.8× 3.3k 0.8× 1.1k 0.6× 163 23.8k
Rafael Rosell 15.2k 0.9× 16.6k 1.0× 10.0k 1.4× 6.0k 1.4× 1.9k 1.1× 546 26.8k
Keunchil Park 17.9k 1.1× 17.0k 1.0× 6.2k 0.9× 4.0k 0.9× 2.8k 1.5× 567 27.4k
Benjamin Solomon 12.7k 0.7× 14.1k 0.8× 6.7k 1.0× 4.3k 1.0× 1.8k 1.0× 415 20.8k
Neal I. Lindeman 11.6k 0.7× 13.2k 0.8× 8.1k 1.2× 5.8k 1.4× 2.6k 1.4× 172 22.4k
Mark A. Socinski 15.1k 0.9× 14.6k 0.9× 4.9k 0.7× 3.0k 0.7× 1.0k 0.6× 518 22.3k
Silvia Novello 11.6k 0.7× 13.0k 0.8× 5.0k 0.7× 3.6k 0.8× 1.3k 0.7× 466 19.1k

Countries citing papers authored by Federico Cappuzzo

Since Specialization
Citations

This map shows the geographic impact of Federico Cappuzzo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Cappuzzo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Cappuzzo more than expected).

Fields of papers citing papers by Federico Cappuzzo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federico Cappuzzo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Cappuzzo. The network helps show where Federico Cappuzzo may publish in the future.

Co-authorship network of co-authors of Federico Cappuzzo

This figure shows the co-authorship network connecting the top 25 collaborators of Federico Cappuzzo. A scholar is included among the top collaborators of Federico Cappuzzo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federico Cappuzzo. Federico Cappuzzo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Landi, Lorenza, et al.. (2025). Antibody-Based Therapeutics in Small Cell Lung Cancer: A Narrative Review. Biologics. Volume 19. 189–199. 1 indexed citations
2.
Gallina, Filippo Tommaso, Daniele Marinelli, Paolo Visca, et al.. (2025). TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma. European Journal of Cancer. 227. 115622–115622.
3.
4.
Cappuzzo, Federico, Gilberto de Castro, Jin‐Hyoung Kang, et al.. (2023). KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC.. Journal of Clinical Oncology. 41(16_suppl). TPS9144–TPS9144. 8 indexed citations
5.
Cornelissen, Robin, Arsela Prelaj, Sophie Sun, et al.. (2023). Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4). Journal of Thoracic Oncology. 18(8). 1031–1041. 34 indexed citations
6.
Cappuzzo, Federico, et al.. (2023). Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. The Oncologist. 28(4). e205–e211. 7 indexed citations
7.
Scott, Jeffrey A., Jochen K. Lennerz, Melissa L. Johnson, et al.. (2023). Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data. JCO Oncology Practice. 20(1). 145–153. 28 indexed citations
8.
Gallina, Filippo Tommaso, Luca Bertolaccini, Shehab Mohamed, et al.. (2022). Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review. Cancers. 14(8). 1949–1949. 6 indexed citations
9.
Landi, Lorenza, Angelo Delmonte, Andrea Bonetti, et al.. (2022). Combi-TED: A new Trial Testing Tedopi ® with Docetaxel or Nivolumab in Metastatic Non-Small-Cell Lung Cancer Progressing After First Line. Future Oncology. 18(40). 4457–4464. 2 indexed citations
10.
Ercolani, Cristiana, Anna Di Benedetto, Paolo Visca, et al.. (2021). Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available. Journal of Clinical Pathology. 75(12). 844–850. 2 indexed citations
11.
Melosky, Barbara, Kato Kambartel, Maik Häntschel, et al.. (2021). Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis. Molecular Diagnosis & Therapy. 26(1). 7–18. 124 indexed citations
12.
Minuti, Gabriele, Silvia Carpano, Ettore D’Argento, et al.. (2021). [Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.]. PubMed. 112(10). 639–646. 1 indexed citations
13.
Solomon, Benjamin, Federico Cappuzzo, Enriqueta Felip, et al.. (2015). Intracranial efficacy of first-line crizotinib vs. chemotherapy in ALK-positive NSCLC. Journal of Thoracic Oncology. 1 indexed citations
14.
Mazières, Julien, Fabrice Barlési, Thomas Filleron, et al.. (2015). Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Annals of Oncology. 27(2). 281–286. 219 indexed citations
15.
Cappuzzo, Federico, Giovanna Finocchiaro, Francesco Grossi, et al.. (2014). Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 10(4). 665–672. 22 indexed citations
16.
Minuti, Gabriele, Armida D’Incecco, & Federico Cappuzzo. (2013). Targeted therapy for NSCLC with driver mutations. Expert Opinion on Biological Therapy. 13(10). 1401–1412. 38 indexed citations
17.
Davies, Kurtis D., Anh T. Le, Mariana F. Theodoro, et al.. (2012). Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(17). 4570–4579. 330 indexed citations
18.
19.
Engelman, Jeffrey A., Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 316(5827). 1039–1043. 3570 indexed citations breakdown →
20.
Cappuzzo, Federico, Vanesa Gregorc, Elisa Rossi, et al.. (2003). Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC. Journal of Clinical Oncology. 21(14). 2658–2663. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Ross Camidge Breakdown of academic impact, for papers by Giorgio V. Scagliotti Breakdown of academic impact, for papers by Lesley Seymour Breakdown of academic impact, for papers by Alan Sandler Breakdown of academic impact, for papers by Rafael Rosell Breakdown of academic impact, for papers by Keunchil Park Breakdown of academic impact, for papers by Benjamin Solomon Breakdown of academic impact, for papers by Neal I. Lindeman Breakdown of academic impact, for papers by Mark A. Socinski Breakdown of academic impact, for papers by Silvia Novello
Rankless by CCL
2026